Phase 3 trial of Covaxin to begin in Haryana on Nov 20, minister Anil Vij offers to be first volunteer

Haryana home minister Anil Vij on Wednesday announced that the third phase trial of Covaxin, Bharat Biotech International Limited’s potential vaccine candidate against the coronavirus disease (Covid-19), will begin on Friday in the state. Vij also offered to be the first volunteer for the vaccine trial.

“Trial for third phase of Covaxin a coronavirus vaccine product of Bhart Biotech to start in Haryana on 20th November. I have offered myself as first volunteer to get vaccinated,” the minister wrote on Twitter.

Bharat Biotech has begun the Phase 3 clinical trials of Covaxin with 26,000 participants across 22 sites in the country, the pharma firm had said on Monday. The Hyderabad-based drug maker is conducting the trial in collaboration with the Indian Council of Medical Research (ICMR).

“The Phase III trials will involve 26,000 volunteers across India, conducted in partnership with ICMR. It is the largest clinical trial conducted for a Covid-19 vaccine in India. This is India’s first phase 3 efficacy study for a Covid-19 vaccine, and the largest phase III efficacy trial ever conducted in India,” Bharat Biotech said in a statement.

The trial has been registered with the clinical trials registry of India and approved by the Drugs Controller General of India (DCGI).

Click here for complete coronavirus coverage

In Haryana, Pandit Bhagwat Dayal Sharma University of Health Sciences in Rohtak and ESIC hospital in Faridabad have been identified among those sites across the country where trials will be conducted, according to Bharat Biotech’s statement.

Trial volunteers, above the age of 18, will receive two intramuscular injections, about 28 days apart. “Participants will be randomly assigned to receive Covaxin or placebo. The trial is double-blinded, such that the investigators, the participants and the company will not be aware of who is assigned to which group,” the pharma firm said.

Covaxin has been evaluated in 1,000 subjects in phase I and phase II clinical trials, with promising safety and immunogenicity data, the statement added.

(With agency inputs)

Disclaimer: This post has not been edited by our staff and is published from a syndicated feed. The Original Source of this post can be found at Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest

Kyrgyzstan accuses Tajikistan of amassing troops near border

Kyrgyzstan accused neighbour Tajikistan on Saturday of building up troops and military equipment near their border, following clashes on...

Oxygen usage: hospitals cautioned on fire hazard

Hospitals advised to update fire safety measures and train staff in handling oxygen All hospitals in the State should immediately update its fire safety measures...

Karnataka HC refuses to quash FIR against former Vice-Chancellor of KSOU

The High Court of Karnataka has declined to quash the criminal case registered against a 76-year-old former Vice-Chancellor of Karnataka State Open University...

CBSE announces marking policy for cancelled class 10 board exams

“Schools indulging in unfair and biased practices for assessment will have to face penalty or disaffiliation.” The Central Board of Secondary Education (CBSE) on...

Actor-anchor Kanupriya dies due to Covid-19 complications

TV actor and anchor Kanupriya passed away due to Covid-19 complications on Friday. The actor, who has appeared on TV shows such as Bhanwar,...

More Articles